TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

About The Tribune-Review
The Tribune-Review can be reached via e-mail or at 412-321-6460.
Contact Us | Video | Photo Reprints

By The Associated Press

Published: Thursday, March 28, 2013, 12:01 a.m.

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Pandora sued by record companies
  2. Chocolate prices expected to soar as ingredients grow more expensive
  3. Squeezed by competition, Chobani to expand offerings
  4. Investment in Western Pa. startups reaches 5-year high
  5. Mazda recalls 109,000 older SUVs
  6. Shale pioneer hires Chesapeake for drilling job
  7. 2014 Beetle is celebration of 65th American anniversary
  8. Pa. unemployment rate falls to lowest since 2008; 12,000 more enter workforce
  9. Under the Hood: A chance to take top cars for a spin
  10. Chrysler’s Easter eggs fun for vehicle owners
  11. Long-term unemployed struggle to find — and keep — new jobs
Subscribe today! Click here for our subscription offers.